MTOR and breast cancer: Furthermore, ABT-263 leads to selective cell death in TP53 wild-type breast cancers after the induction of doxorubicin-induced senescence (50) and activating PIK3CA mutations confer resistance to chemotherapies in TNBC through increased Akt/mTOR signaling and a subsequent reduction in apoptosis (51).